ALAUNOS THERAPEUTICS, INC.

Analyst Reco. Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
1.23 ^USD	-0.81%		-26.35%	+15.98%

Apr. 01	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	North American Morning Briefing : S&P 500 Futures -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	23-08-16	MT
Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	23-08-15	MT
Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	22-10-04	MT
Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	22-07-15	MT
Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	22-05-04	MT
ZIOPHARM ONCOLOGY : Lake Street Adjusts ZIOPHARM Oncology's Price Target to $3.50 From $7, Maintains Buy Rating	21-08-10	MT
ZIOPHARM ONCOLOGY : Raymond James Downgrades ZIOPHARM Oncology to Market Perform From Outperform; Price Target is $3	21-08-10	MT
ZIOPHARM ONCOLOGY : Raymond James Adjusts Price Target on ZIOPHARM Oncology to $4 From $5.50, Maintains Outperform Rating	21-05-07	MT
ZIOPHARM ONCOLOGY : Jefferies Downgrades ZIOPHARM Oncology to Hold Rating From Buy, Adjusts Price Target to $5 From $7	21-03-12	MT
ZIOPHARM ONCOLOGY : HC Wainwright Downgrades ZIOPHARM Oncology to Neutral From Buy	21-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer